Matthew Carabasi is an Oncology physician affiliated with Thomas Jefferson University. OpenAlex indexes 103 publications with 2,762 citations (h-index 20); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
925 Chestnut St
Suite 320a
Philadelphia, PA 191074216
Telephone
215-955-8874Registry record last updated 13 Mar 2014.
Clinical trials
- Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Pharmacyclics LLC, an AbbVie CompanyProgram year20221 payment
- Novartis Pharmaceuticals CorporationProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2010–2012 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Prospective, Randomized Trial Examining the Use of G-CSF Versus No G-CSF in Patients Post-Autologous Transplantation
Biology of Blood and Marrow Transplantation
2022 - Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies
Bone Marrow Transplantation
2022 - PSMA targeted armored chimeric antigen receptor (CAR) T-cells in patients with advanced mCRPC: A phase I experience.
Journal of Clinical Oncology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Carol Shields, MD
Thomas Jefferson University
Joseph Bavaria, MD
Thomas Jefferson University
Michele Meltzer, MD
Thomas Jefferson University
Marinos Dalakas, MD
Thomas Jefferson University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”